Objective: To identify which specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
effects include white race; better physical functioning; better performance on attention, immediate, and delayed memory tests; greater psychomotor agitation and suicidality symptoms; and a history of adequate antidepressant pharmacotherapy. 9 The identification of other clinical characteristics that predict remission can help guide treatment decisions for LLTRD. One such method of assessing clinical characteristics can be accomplished through the use of individual items of depressive symptom severity, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). 10 The MADRS assesses 10 symptoms of depression: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. 11 To date, no studies have looked at each item on the MADRS as a predictor of remission with aripiprazole augmentation. These depressive symptoms are routinely assessed in clinical care, even when structured measures are not used.
Identifying which of these depressive symptoms predict remission has high relevance for clinical care. Therefore, we sought to explore (1) which baseline depressive symptoms, using individual MADRS items, predict remission and (2) if combinations of the clinically significant depressive symptoms using baseline MADRS items improve the precision of predicting remission with treatment.
| METHODS
We used data from the Incomplete Response in Late-Life Depression:
Getting to Remission (IRL-GRey) study. The IRL-GRey was a 12-week, 
| Intervention
Late-life treatment resistant depression was established in 181 participants who did not achieve remission following open-label treatment with extended release venlafaxine, up to 300 mg a day for 12 weeks.
Remission was defined as a MADRS score less than or equal to 10 for 2 sequential assessments. In the second phase, treatment with venlafaxine at the same dose received during the acute treatment phase was continued, and participants were randomly assigned (using permuted block randomization) to augmentation with aripiprazole or placebo for 12 weeks. Aripiprazole or placebo tablets were started at 2 mg per day and titrated as tolerated and as needed to a maximum dose of 15 mg per day. The randomized augmentation phase was conducted under double-blind conditions and outcomes were assessed by independent evaluators. The pharmacist was the only member of the research team aware of treatment assignment. 
| Depression assessment

| Statistical analyses
The analyses were conducted separately with the 91 participants who received aripiprazole augmentation and the 90 who received placebo.
To identify which of the 10 MADRS items predicted remission, participants were dichotomized into those who remitted versus those who did not remit. Baseline MADRS item scores were dichotomized into clinically symptomatic (ie, item scores 3-6) or not clinically symptomatic (scores 0-2) to identify groups with high and low symptom severity as that translates to the clinical setting. Logistic regression analysis was used to estimate the relationship of predictive factors (ie, MADRS
Key points
• The identification of specific depressive symptoms, which can be clinically assessed, can be used to inform treatment decisions.
• Older adults with treatment resistant depression that present with sleep disturbances, lack of apparent sadness, and lack of inability to feel should be considered for aripiprazole augmentation.
• These 3 predictors are specific to remission with aripiprazole treatment as they did not predict improvement with placebo.
items) with the odds of remission. Remission was the dependent variable, with individual baseline MADRS items (dichotomized as symptomatic and nonsymptomatic) entered as predictive variables. All predictive factors were simultaneously entered into the model with study site as a covariate. Odds ratios and 95% confidence intervals were estimated. To explore the combination of significant predictors on odds of remission, interaction terms were subsequently entered into model. Lastly, to confirm that our findings were unique to the aripiprazole augmentation group, the above analyses were repeated in the placebo group.
| RESULTS
Please see Table 1 for the demographic and clinical characteristics of the full sample and stratified by treatment condition. Participants had a mean (SD) age of 67.4 (6.1) years; they were mostly white (57%), female (88%), and had a mean (SD) of 14. Table 2 for the distribution of participants by treatment arm, baseline symptomatic and nonsymptomatic groups, and treatment outcome for items 1, 4, and 8.
| Combinations of baseline MADRS items as predictors of remission with aripiprazole augmentation
Two-way interaction terms consisting of the different combinations among items 1, 4, and 8 were all nonsignificant: items 1 and 4 (z = .86, P = .4), items 4 and 8 (z = −1.45, P = .1), items 1 and 8
(z = −.99, P = .3). Similarly, the 3-way interaction term between the 3 significant items was not significant (z = −1.67, P = .1).
| Baseline MADRS items as predictors of remission in those receiving placebo
As before, due to limited variability in item response, items 2 (ie, 100% were symptomatic) and 10 (ie, 92% were asymptomatic) were omitted from analyses. In the placebo group, all the MADRS item scores were non-significant predictors of remission (P values ranged from 0.14 to 0.95).
| DISCUSSION
Among depressed older adults who have failed to respond to first line treatment with venlafaxine, those who presented with sleep disturbances and absence of apparent sadness or inability to feel were more likely to remit with aripiprazole augmentation. However, having a combination of these three predictors did not increase the precision of predicting likelihood of remission beyond any of the single items.
Furthermore, these three predictors were specific to aripiprazole treatment: they did not predict improvement with placebo.
Sleep disturbances are common in late-life, affecting approximately 50% of older adults. 13 They frequently occur with other psychiatric disorders such as major depression. 13 In this group, 70% of participants had symptomatic sleep disturbances. Epidemiologic studies support a bidirectional association between sleep and depression.
14 As such, older adults with sleep disturbances are more likely to become depressed and those with depression are more likely to develop sleep disturbances. 15 Our finding of better response in those with sleep disturbance in this treatment-resistant group are consistent with our previous findings in the larger IRL-GRey group: with venlafaxine monotherapy, better subjective sleep was associated with a worse response trajectory. 16 These findings may be explained by sleep disturbances being a symptomatic marker of a subtype of late-life depression requiring and responding to pharmacotherapy. 17 Given the bidirectional nature of the relationship between depression and sleep, and the fact that sleep disturbances may predate a depressive episode, 18 treating sleep disturbances in the setting of depression is clinically important.
By contrast, absence of apparent sadness and inability to feel were associated with a higher likelihood of remission with aripiprazole augmentation. This did not simply reflect a nonspecific association (ie, less symptomatic patients did better) since it was not observed with placebo. We did not expect this association since it has been hypothesized that "dopaminergic" symptoms of depression, such as psychomotor retardation, lassitude, and inability to feel are responsive to aripiprazole augmentation through potentiation of dopaminergic activity. 19 It may be possible that participants without "apparent sadness" (eg, psychomotor retardation) or "inability to feel" already had more activated dopaminergic circuits, which facilitated the response to aripiprazole. Alternatively, it is possible that the proposed mechanism of action of aripiprazole in LLTRD is more complex and that patients with symptoms reflecting decreased dopaminergic function (ie, psychomotor retardation and inability to feel) do more poorly when treated with it.
There are several limitations to this study. First, our N was small.
Second, the generalizability of our results are limited to older adults with similar clinical and demographic characteristics of our sample.
Therefore, these finding should be replicated in other samples. Third, the MADRS sleep item may not adequately represent or measure sleep pathology in older adults, although it has been used elsewhere in the literature. 16 Lastly, while the sleep item was significant in the multivariate regression which included all the items, it only trended towards significance in the univariate analysis to predict remission. This could likely be due to the interactive effect of other symptoms and sites. 
